# A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

> **NCT02207374** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 601 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** DPP-4 inhibitor

## Key facts

- **NCT ID:** NCT02207374
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-04
- **Primary completion:** 2016-02-27
- **Final completion:** 2016-02-27
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207374, "A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02207374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*